Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Acceleron Pharma Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2004
Status: Acquired
BioCentury | May 29, 2024
Deals
Clinical readout spurred Merck’s $1.3B takeout of VC-backed ophthalmic play EyeBio
In milestone-heavy deal worth up to $3B total, the pharma makes a big commitment to late-stage candidate for retinal diseases
BioCentury | Mar 26, 2024
Regulation
Merck’s sotatercept approval brings vascular remodeling to PAH
Approval marks the start of a new disease-modifying treatment paradigm for the rare disease and related indications
BioCentury | Feb 21, 2024
Product Development
Rare disease spotlight: treating a facial muscular dystrophy at its root
As the most advanced FSHD programs aim to reduce muscle cell death, the next wave is targeting the disease’s genetic cause
BioCentury | Sep 29, 2023
Regulation
Sept. 28 Quick Takes: FDA approves Amicus’ Pompe disease therapy
Plus: J&J’s Rybrevant raises the bar and updates from Harbinger, Gritstone, Merck, Immunovant, Evozyne, PTC
BioCentury | Mar 7, 2023
Deals
March 6 Quick Takes: Adaptimmune acquiring TCR2 Therapeutics
Plus: BridgeBio gains on oral achondroplasia therapy data and updates from Esperion, Aclaris, Merck & Co., Voyager and more
BioCentury | Feb 7, 2023
Management Tracks
Okamura to lead Astellas
Plus: Myers at the helm of Viridian, and updates from Novartis,
BioCentury | Dec 22, 2022
Management Tracks
Genentech bolsters marketing team
Plus: Greene becomes chief investment officer at Hevolution, and updates from Aerami and Curate
BioCentury | Nov 18, 2022
Management Tracks
Cagnoni now CEO at Flagship’s Laronde
Plus: New commercial head at Valneva, and updates from Aeglea and Viridian
BioCentury | Nov 11, 2022
Management Tracks
Sage’s Jonas becomes CEO of CBC-backed incubator ABio-X
Plus: McKinsey vet Fleming joins Enavate and updates from Scholar Rock, Acelyrin and Anpac
BioCentury | Oct 11, 2022
Product Development
PAH treatment moves in a disease-modifying direction with Merck data
Sotatercept meets primary and most secondary endpoints in Phase III pulmonary arterial hypertension study
Items per page:
1 - 10 of 235